Physician profile
Ernest Bloom
NPI 1306941620
$4,266.40
in general payments reported to CMS, 2019-2025
14 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what 79% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $351 · 2021: $315 · 2022: $404 · 2023: $485 · 2024: $958 · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,604 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,604.39 |
| Education | $121.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $1,774.72 | 2019-2025 | Adbry |
| Abbvie INC. | $804.80 | 2019-2025 | Skyrizi |
| Pfizer INC. | $456.28 | 2019-2025 | |
| Amgen INC. | $318.54 | 2019-2020 | |
| Janssen Biotech, INC. | $277.94 | 2021-2024 | Tremfya |
| Lilly USA, LLC | $170.53 | 2021-2023 | Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $110.15 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $101.10 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $81.07 | 2019 | |
| Dermavant Sciences, INC. | $52.95 | 2024 | Vtama |
| Organon LLC | $47.70 | 2025 | Vtama |
| Genzyme Corporation | $30.70 | 2021-2022 | |
| Incyte Corporation | $27.70 | 2023 | Opzelura |
| Strata Skin Sciences, INC. | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.